ES (S&P 500) S&P 500 correction is over. We not only managed to make ...
It seems that the time of the rally in pharmaceutical stocks is out. But this is only at first glance. There are excellent investment ideas in particular securities.
For example, AbbVie, a biopharmaceutical company in the USA, which is engaged in a lot of research and development. After the separation from Abbott Laboratories, there were doubts about the sustainability of the business, but already in 2020, with the acquisition of Allergan, AbbVie’s positions became stronger. The main bet is on medicines to fight hepatitis C, arthritis, HIV, Parkinson’s disease, etc.
It is worth noting that in this case, the risks are the same for almost all US securities.
The technical picture of ABBV trading suggests a local increase to $170 per share at today’s price of $154.
The MACD indicator develops growth in the neutral zone and strengthens the buy signal. The Stochastic oscillator has entered the overbought zone and signals a purchase.